The goal of this clinical trial is to determine the relative efficacy of fMRI model guided Transcranial Direct Current Stimulation (mgTDCS) in improving the depressive symptoms of patients with Parkinson's Disease (PD). The main questions it aims to answer are: 1) Can the use of mgTDCS significantly improve the self-reported level of depression and apathy in patients with PD from pre-intervention to post-intervention compared to a sham control? 2) Can the use of mgTDCS significantly normalize the cortical eeg alpha asymmetry so commonly seen in depressed patients compared to sham mgTDCS? 3) Can the use of mgTDCS significantly improve scores on neuropsychological tests of working memory?
This study seeks to expand the growing body of literature on the use of a particular type of low voltage electrical stimulation known as Transcranial Direct Current Stimulation (TDCS) to reduce the symptoms of Parkinson's Disease (PD). One common disorder that can result from, and/or be exacerbated by PD is Major Depressive Disorder. In particular, apathy has been noted as a common and detrimental component for those with PD. While many studies have been performed on PD patients using TDCS, the consensus in the literature is that results are widely variable. Participants will: * complete self-report measures and neuropsychological tests * undergo eeg recording pre and post intervention * participate in 15, 46 minute sessions (2 13 minute stimulation sessions with 20 minutes of rest between) of mgTDCS over the course of 4-5 weeks Researchers will compare active mgTDCS to Sham mgTDCS to see if active mgTDCS is more effective. A non Parkinson's group of depressed controls who are age-matched to the PD patients will serve to determine if treatment effects are specific to PD or generalize to depression more generally.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
40
Transcranial Electrical Stimulator
Transcranial Electrical Stimulator set to 0 amps
University of South Alabama
Mobile, Alabama, United States
RECRUITINGBeck Depression Inventory (BDI) Pre-post change score
The BDI, a self-report measure for assessing depression, has high internal consistency (Cronbach's alpha \> .90) and good test-retest reliability.
Time frame: One at Day 1 and one after 15 sessions of training, typically 4 weeks after study start.
Alpha band power pre-post change score
Alpha band power from pre-post eeg records will be assessed for power changes at frontal sites.
Time frame: One at Day 1 and one after 15 sessions of training, typically 4 weeks after study start.
RBANS Working Memory
Digit Span and Story Memory subtests will be used to determine changes in working memory.
Time frame: One at Day 1 and one after 15 sessions of training, typically 4 weeks after study start.
PDQ-39
This a common measure to assess patient quality of life in Parkinson Disease patients involved in research.
Time frame: One at Day 1 and one after 15 sessions of training, typically 4 weeks after study start.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.